OXYCODONE HYDROCHLORIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H21NO4.ClH
Molecular Weight	351.825
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.[H][C@@]12OC3=C4C(C[C@@]5([H])N(C)CC[C@@]14[C@@]5(O)CCC2=O)=CC=C3OC

InChI

InChIKey=MUZQPDBAOYKNLO-RKXJKUSZSA-N

InChI=1S/C18H21NO4.ClH/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10;/h3-4,13,16,21H,5-9H2,1-2H3;1H/t13-,16+,17+,18-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	C18H21NO4
Molecular Weight	315.3636
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202080s005s006lbl.pdf
Curator's Comment: description was created based on several sources, including http://reference.medscape.com/drug/oxycontin-xtampza-er-oxycodone-343321 | https://www.ncbi.nlm.nih.gov/pubmed/23880538 | https://www.drugs.com/oxycodone.html

Oxycodone is a semisynthetic opioid used for the management of acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Oxycodone is a highly selective full agonist of the μ-opioid receptor (MOR), with low affinity for the δ-opioid receptor (DOR) and κ-opioid receptor (KOR). After oxycodone binds to the MOR, a G protein-complex is released, which inhibits the release of neurotransmitters by the cell by reducing the amount of cAMP produced, closing calcium channels, and opening potassium channels. After a dose of conventional (instant-release) oral oxycodone, the onset of action is 10–30 minutes, and peak plasma levels of the drug are attained within roughly 30–60 minutes in contrast, after a dose of OxyContin (an oral controlled-release formulation), peak plasma levels of oxycodone occur in about three hours. The duration of instant-release oxycodone is 3 to 6 hours, although this can be variable depending on the individual. Oxycodone in the blood is distributed to skeletal muscle, liver, intestinal tract, lungs, spleen, and brain. Serious side effects of oxycodone include reduced sensitivity to pain (beyond the pain the drug is taken to reduce), euphoria, anxiolysis, feelings of relaxation, and respiratory depression. Common side effects of oxycodone include constipation (23%), nausea (23%), vomiting (12%), somnolence (23%), dizziness (13%), itching (13%), dry mouth (6%), and sweating (5%).

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Mu opioid receptor 221 Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23880538	Agonist 2678	500.0 nM [EC50]
Kappa opioid receptor 108 Target ID: CHEMBL237 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23880538	Agonist 2678	16000.0 nM [EC50]
Delta opioid receptor 77 Target ID: CHEMBL236 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23880538	Agonist 2678	4000.0 nM [EC50]

Conditions

Condition	Modality	Highest Phase	Product
Acute and chronic pain 6 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202080s005s006lbl.pdf	Primary	Approved 8429	PERCODAN-DEMI Approved Use OxyContin Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. OxyContin is NOT intended for use as a prn analgesic. Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for HealthCare Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. OxyContin is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. OxyContin is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.) Launch Date -6.224256E11
Opioid-related disorders 6 Sources: https://clinicaltrials.gov/ct2/show/NCT00158184	Primary	Phase II 1132	PERCODAN-DEMI Approved Use OxyContin Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. OxyContin is NOT intended for use as a prn analgesic. Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for HealthCare Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. OxyContin is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. OxyContin is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.) Launch Date -6.224256E11
Osteoarthritis 157 Sources: https://clinicaltrials.gov/ct2/show/NCT00985621	Primary	Phase III 656	PERCODAN-DEMI Approved Use OxyContin Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. OxyContin is NOT intended for use as a prn analgesic. Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for HealthCare Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. OxyContin is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. OxyContin is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.) Launch Date -6.224256E11

C_max

Value	Dose	Analyte	Population
19 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE unknown	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED
22.2 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE unknown	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
17.7 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE unknown	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FED
39.3 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE unknown	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
15.7 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	5 mg 4 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXYCODONE unknown	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
12.9 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	3.33 mg 6 times / day steady-state, oral dose: 3.33 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXYCODONE unknown	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
105 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE unknown	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED
128.2 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE unknown	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
133 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE unknown	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FED
268.2 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE unknown	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
113.3 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	5 mg 4 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXYCODONE unknown	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
99 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	3.33 mg 6 times / day steady-state, oral dose: 3.33 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXYCODONE unknown	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
2.9 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE unknown	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED
3.55 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE unknown	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
3.3 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE unknown	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FED
3.85 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE unknown	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Analyte	Population
55% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE unknown	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED
55% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE unknown	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
55% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE unknown	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FED
55% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYCODONE unknown	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
55% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	5 mg 4 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXYCODONE unknown	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
55% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	3.33 mg 6 times / day steady-state, oral dose: 3.33 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXYCODONE unknown	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
30 mg 1 times / day single, oral Studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Co-administed with:: acetaminophen(1950 mg; single) cocaine(1/4 g; single) Sources: https://pubmed.ncbi.nlm.nih.gov/1994955/	healthy, 30 years n = 1 Health Status: healthy Age Group: 30 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/1994955/	Other AEs: Pulmonary edema... Other AEs: Pulmonary edema Sources: https://pubmed.ncbi.nlm.nih.gov/1994955/
20 mg 2 times / day multiple, oral (mean) Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf Page: /nda/98/20932_medr_P2.pdf - p.21	unhealthy, adult n = 120 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 120 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf Page: /nda/98/20932_medr_P2.pdf - p.21	Disc. AE: Nausea, Dizziness... AEs leading to discontinuation/dose reduction: Nausea (grade 1-2, 1.7%) Dizziness (grade 1-2, 1.7%) Abdominal pain (grade 1-2, 0.8%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf Page: /nda/98/20932_medr_P2.pdf - p.21
20 mg 2 times / day multiple, oral (mean) Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf Page: /nda/98/20932_medr_P2.pdf - p.21	unhealthy, adult n = 125 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 125 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf Page: /nda/98/20932_medr_P2.pdf - p.21	Disc. AE: Headache, Vomiting... AEs leading to discontinuation/dose reduction: Headache (grade 1-2, 0.8%) Vomiting (grade 1-2, 0.8%) Nausea (grade 1-2, 0.8%) Somnolence (grade 1-2, 0.8%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf Page: /nda/98/20932_medr_P2.pdf - p.21
5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf Page: /nda/98/20932_medr_P2.pdf - p.21	unhealthy, adult n = 63 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 63 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf Page: /nda/98/20932_medr_P2.pdf - p.21	Disc. AE: Nausea, Dizziness... AEs leading to discontinuation/dose reduction: Nausea (grade 1-2, 6.3%) Dizziness (grade 1-2, 4.8%) Confusion (grade 1-2, 3.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf Page: /nda/98/20932_medr_P2.pdf - p.21
5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf Page: /nda/98/20932_medr_P2.pdf - p.21	unhealthy, adult n = 126 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 126 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf Page: /nda/98/20932_medr_P2.pdf - p.21	Disc. AE: Vomiting, Flu syndrome... AEs leading to discontinuation/dose reduction: Vomiting (grade 1-2, 0.8%) Flu syndrome (grade 1-2, 0.8%) Confusion (grade 1-2, 0.8%) Fatigue (grade 1-2, 0.8%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf Page: /nda/98/20932_medr_P2.pdf - p.21
6 mg 2 times / day single, oral (mean) Studied dose Dose: 6 mg, 2 times / day Route: oral Route: single Dose: 6 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202080Orig1s000MedR.pdf https://pubmed.ncbi.nlm.nih.gov/22717418/	healthy, mean age 33 years n = 35 Health Status: healthy Age Group: mean age 33 years Sex: M+F Population Size: 35 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202080Orig1s000MedR.pdf https://pubmed.ncbi.nlm.nih.gov/22717418/	Disc. AE: Vomiting... AEs leading to discontinuation/dose reduction: Vomiting (11.4%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202080Orig1s000MedR.pdf https://pubmed.ncbi.nlm.nih.gov/22717418/
15 mg 1 times / day single, oral Studied dose Dose: 15 mg, 1 times / day Route: oral Route: single Dose: 15 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202080Orig1s000MedR.pdf Page: nda/2011/202080Orig1s000MedR.pdf - p.22	healthy, mean age 36 years n = 40 Health Status: healthy Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202080Orig1s000MedR.pdf Page: nda/2011/202080Orig1s000MedR.pdf - p.22	Disc. AE: Vomiting... AEs leading to discontinuation/dose reduction: Vomiting (2.5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202080Orig1s000MedR.pdf Page: nda/2011/202080Orig1s000MedR.pdf - p.22

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737		substrate 1217	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
Nav1.5 97	CYP3A5 395 P-gp 1537 UGT2B7 389 UGT2B4 249	P-gp 257 BCRP 75

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
BCRP 773	inducer 1573 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802418/	yes
P-gp 1650	inducer 1573 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401600/	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
UGT2B7 389	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/27692933/	major
UGT2B4 249	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/27692933/	minor
CYP3A5 395	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15039299/	yes
P-gp 1537	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401600/	yes
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21011lbl.pdf#page=7; https://pubmed.ncbi.nlm.nih.gov/21142269/ Page: 7.0	yes	yes (co-administration study) Comment: When both oxidative pathways of the metabolism of oxycodone were inhibited with paroxetine and itraconazole (CYP3A4 AND CYP2D6 inhibitors), the mean AUC(0,∞) of oxycodone increased by 2.9-fold (P < 0.001), and its Cmax by 1.8-fold (P < 0.001). Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21011lbl.pdf#page=7; https://pubmed.ncbi.nlm.nih.gov/21142269/ Page: 7.0
CYP3A4 1737	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15039299/; https://pubmed.ncbi.nlm.nih.gov/21142269/	yes	yes (co-administration study) Comment: When both oxidative pathways of the metabolism of oxycodone were inhibited with paroxetine and itraconazole (CYP3A4 AND CYP2D6 inhibitors), the mean AUC(0,∞) of oxycodone increased by 2.9-fold (P < 0.001), and its Cmax by 1.8-fold (P < 0.001). Sources: https://pubmed.ncbi.nlm.nih.gov/15039299/; https://pubmed.ncbi.nlm.nih.gov/21142269/

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
Nav1.5 100	inhibitor 1626 Sources: https://europepmc.org/article/med/29722437
hERG 1647	inhibitor 1626 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670374/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:7852	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7852
ZINC	ZINC000000403533	http://zinc15.docking.org/substances/ZINC000000403533

PubMed

Title	Date	PubMed
Advancement of opioid analgesia with controlled-release oxycodone.	2001	11798230
Opioid formulations: tailoring to the needs in chronic pain.	2001	11798229
Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis.	2001	11438043
A randomized trial of controlled-release oxycodone during inpatient rehabilitation following unilateral total knee arthroplasty.	2001 Apr	11315787
Time-release analgesic drug causes fatal overdoses in United States.	2001 Aug	11483541
A curse and a cure. Is the crackdown on an abused drug causing needless suffering?	2001 Aug 6	11499370
Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.	2001 Feb	11210406
Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition.	2001 Feb	11210403
The 'poor man's heroin'. An Ohio surgeon helps feed a growing addiction to OxyContin.	2001 Feb 12	11216230
Profits vs. pain relief.	2001 Jul 2	11447813
Relative variability in bioavailability of oral controlled-release formulations of oxycodone and morphine.	2001 Jul-Aug	11441321
A retrospective study of the effect of postoperative indomethacin rectal suppositories on the need for narcotic analgesia in patients who had a cesarean delivery while they were under regional anesthesia.	2001 Jun	11408878
I.v. ketoprofen for analgesia after tonsillectomy: comparison of pre- and post-operative administration.	2001 Mar	11573528
Narcotic analgesics for dental pain: available products, strengths, and formulations.	2001 Mar-Apr	12004688
Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients.	2001 May	11361046
OxyContin, the media, and law enforcement.	2001 May-Jun	11406885
Interscalene brachial plexus block with continuous intraarticular infusion of ropivacaine.	2001 Sep	11524326
Oxycodone/ibuprofen.	2002	11881533
Capillary electrophoresis and capillary electrophoresis-ion trap multiple-stage mass spectrometry for the differentiation and identification of oxycodone and its major metabolites in human urine.	2002 Apr 25	12013227
Nasal administration of opioids for pain management in adults.	2002 Aug	12139528
A rapid and sensitive high-performance liquid chromatography-electrospray ionization-triple quadrupole mass spectrometry method for the quantitation of oxycodone in human plasma.	2002 Jan	11866386
Combination hydrocodone and ibuprofen versus combination oxycodone and acetaminophen in the treatment of moderate or severe acute low back pain.	2002 Jan	11833838
Gateways to clinical trials.	2002 Jul-Aug	12224444
OxyContin and neonatal abstinence syndrome.	2002 Jun	12032797
An evaluation of the efficacy and tolerability of oral tramadol hydrochloride tablets for the treatment of postsurgical pain in children.	2002 Jun	12032009
OxyContin Use and Abuse.	2002 Mar-Apr	11889673
Preoperative administration of controlled-release oxycodone for the management of pain after ambulatory laparoscopic tubal ligation surgery.	2002 May	12031758
Simultaneous quantitation of opioids in blood by GC-EI-MS analysis following deproteination, detautomerization of keto analytes, solid-phase extraction, and trimethylsilyl derivatization.	2002 Oct	12423011
Detection of cocaine analytes and opiates in nails from postmortem cases.	2002 Oct	12423005
Oxycontin: the concept of a "ghost pill" and the postmortem tissue distribution of oxycodone in 36 cases.	2002 Oct	12422999
Propacetamol as adjunctive treatment for postoperative pain after cardiac surgery.	2002 Oct	12351250

Patents

Sample Use Guides

In Vivo Use Guide

For opioid naïve patients, initiate treatment with 5 mg to 15 mg every 4 to 6 hours as needed for pain.

Route of Administration: Oral

In Vitro Use Guide

Human embryonic kidney (HEK)-293 were used for activity evaluation. Receptor G protein-mediated responses were determined by measuring changes in cAMP using the cAMP–homogenous timeresolved fluorescence kit (Cisbio, Codolet, France). MOR, KOR, DOR all couple to Gai so G protein coupling was measured as inhibition of forskolin-stimulated cAMP accumulation in the presence of 1.5 mkM NKH-477 (water-soluble forskolin, Tocris catalog #1603) and 500 mkM 3-isobutyl-1-methylxanthine (IBMX). cAMP accumulation assays were run in parallel with b-arrestin-2 recruitment, using the same cells, drug dilutions, and assay buffers [1% dimethylsulfoxide (DMSO), F12 Ham’s buffer] to ensure accurate assay-to-assay comparisons of data. Plates were read using a time-resolved fluorescence ratio (665 nm/620 nm) on a PheraStar plate reader

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:04:36 UTC 2023` Edited by `admin` on `Fri Dec 15 15:04:36 UTC 2023`
Record UNII	C1ENJ2TE6C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OXYCODONE HYDROCHLORIDE

Official Name

English

OXYCODONE HYDROCHLORIDE [USAN]

Common Name

English

OXYCODONE HYDROCHLORIDE COMPONENT OF XARTEMIS

Brand Name

English

OXYCODONE HYDROCHLORIDE COMPONENT OF OXYCET

Common Name

English

ROXIPRIN COMPONENT OXYCODONE HYDROCHLORIDE

Common Name

English

OXYCODONE HYDROCHLORIDE [MI]

Common Name

English

MORPHINAN-6-ONE, 4,5-EPOXY-14-HYDROXY-3-METHOXY-17-METHYL-, HYDROCHLORIDE, (5.ALPHA.)-

Systematic Name

English

OXYCODONE HYDROCHLORIDE CII [USP-RS]

Common Name

English

OXYCODONE HYDROCHLORIDE [MART.]

Common Name

English

COMBUNOX COMPONENT OXYCODONE HYDROCHLORIDE

Common Name

English

OXYCODONE HYDROCHLORIDE [EP MONOGRAPH]

Common Name

English

OXYCODONE HYDROCHLORIDE COMPONENT OF TARGINIQ

Brand Name

English

4,5α-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride

Systematic Name

English

OXYCET COMPONENT OXYCODONE HYDROCHLORIDE

Common Name

English

ANHYDROUS OXYCODONE HYDROCHLORIDE

Common Name

English

OXYCODONE HYDROCHLORIDE COMPONENT OF ROXILOX

Common Name

English

TROXYCA COMPONENT OXYCODONE HYDROCHLORIDE

Brand Name

English

OXYCODONE HYDROCHLORIDE COMPONENT OF ROXIPRIN

Common Name

English

OXYCODONE HYDROCHLORIDE [VANDF]

Common Name

English

OXYCODONE HYDROCHLORIDE COMPONENT OF TYLOX

Common Name

English

TARGINIQ COMPONENT OXYCODONE HYDROCHLORIDE

Brand Name

English

OXECTA

Brand Name

English

OXYCODONE HCL

Common Name

English

CODOXY COMPONENT OXYCODONE HYDROCHLORIDE

Common Name

English

OXYCODONE HYDROCHLORIDE COMPONENT OF PERCODAN

Common Name

English

OXYCODONE HYDROCHLORIDE COMPONENT OF PERCODAN-DEMI

Common Name

English

PERCODAN-DEMI COMPONENT OXYCODONE HYDROCHLORIDE

Common Name

English

OXYCODONE HYDROCHLORIDE COMPONENT OF COMBUNOX

Common Name

English

PERCODAN COMPONENT OXYCODONE HYDROCHLORIDE

Common Name

English

Oxycodone hydrochloride [WHO-DD]

Common Name

English

XARTEMIS COMPONENT OXYCODONE HYDROCHLORIDE

Brand Name

English

ROXICET COMPONENT OXYCODONE HYDROCHLORIDE

Common Name

English

OXYCONTIN

Brand Name

English

OXYCODONE HYDROCHLORIDE COMPONENT OF ROXICET

Common Name

English

ROXICODONE

Brand Name

English

PERCOCET COMPONENT OXYCODONE HYDROCHLORIDE

Common Name

English

OXYCODONE HYDROCHLORIDE COMPONENT OF CODOXY

Common Name

English

OXYCODONE HYDROCHLORIDE COMPONENT OF TROXYCA

Brand Name

English

ROXYBOND

Brand Name

English

ENDOCODONE

Brand Name

English

TYLOX COMPONENT OXYCODONE HYDROCHLORIDE

Common Name

English

ROXILOX COMPONENT OXYCODONE HYDROCHLORIDE

Common Name

English

OXYCODONE HYDROCHLORIDE CII

Common Name

English

OXYCODONE HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

OXYCODONE HYDROCHLORIDE [USP MONOGRAPH]

Common Name

English

OXYCODONE HYDROCHLORIDE COMPONENT OF PERCOCET

Common Name

English

Classification Tree Code System Code

DEA NO.

9143